PHP
BMY icon

Parkman Healthcare Partners’s Bristol-Myers Squibb BMY Stock Holding History

Parkman Healthcare Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200,000
Closed -$8.31M – 94
2024
Q2 		$8.31M Buy
+200,000
New +$8.95M 1.11% 36
2024
Q1 		– Sell
-100,000
Closed -$5.13M – 103
2023
Q4 		$5.13M Buy
+100,000
New +$5.25M 0.72% 44

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parkman Healthcare Partners's BMY Position: Q3 2024 in Review

Parkman Healthcare Partners sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 200,000 shares — an estimated $8.31M sold.

Parkman Healthcare Partners first reported a position in BMY in Q4 2023 and held it in 2 quarters. The position peaked at $8.31M in Q2 2024. 2,259 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

  • Parkman Healthcare Partners reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 200,000 Bristol-Myers Squibb shares in Q3 2024, an estimated $8.31M.
  • Parkman Healthcare Partners first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 2 quarters.
  • Parkman Healthcare Partners's Bristol-Myers Squibb position peaked at $8.31M in Q2 2024.
  • 2,259 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Parkman Healthcare Partners's 13F filing for Q3 2024, filed 14 Nov 2024.